Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Ohara’s High-Need Pediatric Cancer Drug in Limbo 2 Years after Approval due to GMP Issue
February 15, 2019
- Kowa to Reshuffle Pharma Business in April, Launching New Company for LLP Operations
February 15, 2019
- Armed with Positive Data, G47Δ Could Reach Filing in May as Japan’s 1st Oncolytic Virus
February 14, 2019
- Recordati Ratcheting Up Japan Biz, Set to Enrich Rare Disease Portfolio
February 14, 2019
- Upbeat Global Brands Drive Otsuka Sales in 2018
February 14, 2019
- GSK Japan’s Fauchet Bows Out as Chairman
February 14, 2019
- Avanir, DOJ Reach Agreement over Nuedexta Marketing Activity Case
February 14, 2019
- Eisai Files Fycompa in Europe for Pediatric Use
February 14, 2019
- MSD Files Keytruda/Inlyta Combo in Japan as 1st-Line Therapy for RCC
February 14, 2019
- Generic Player Ohara Looks to Morph into Innovative Drug Maker, with Focus on Oncology
February 13, 2019
- Takeda’s Adcetris Gets European OK for 1st-Line Stage IV Hodgkin’s Lymphoma
February 13, 2019
- Astellas/Pfizer Unveil Positive Xtandi Data for Hormone-Sensitive Prostate Cancer
February 13, 2019
- Oncolys in Talks with Checkpoint Drug Makers for Telomelysin: President
February 12, 2019
- US Latuda Sales Might Fall Short as Lawsuits Weigh: Sumitomo Dainippon Chief
February 12, 2019
- Xofluza Top Seller in Japan in January: Encise Snapshot
February 12, 2019
- Mochida Seeks Label Expansion for Dinagest in Japan
February 12, 2019
- Pfizer Initiates Voluntary Recall of Exforge Generics after Discovery of Carcinogenic Substances Above Limits
February 12, 2019
- Sumitomo Dainippon, Aikomi Join Forces for Research on Medical Devices to Relieve BPSD
February 12, 2019
- Ethical Drug Sales Down 4.5% in December: Crecon
February 8, 2019
- SymBio Targets 11.8 Billion Yen Sales in 2022 under New 4-Year Biz Plan
February 8, 2019
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…